Acelyrin PsA Data Are Positive, But Is Its IL-17 Blocker Competitive?

 
• By Joseph Haas
  
Psoriatic arthritis
Acelryin hopes izokibep will be competitive in the PsA space • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D